Canntab Therapeutics Limited

Healthcare US CTABF

NoneUSD
0.00(0%)

Last update at 2026-01-01T20:01:06.342131Z

Day Range

LowHigh

52 Week Range

0.00210.02

LowHigh

Fundamentals

Previous Close -
Market Cap0.35M
VolumeNone
P/E Ratio-
Dividend Yield-%
EBITDA-3.02831M
Revenue TTM0.07M
Revenue Per Share TTM0.002
Gross Profit TTM -0.93901M
Diluted EPS TTM-0.07

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31
Income before tax	-3.68919M	-4.41978M	-2.60724M	-2.45858M	-2.40841M
Minority interest	-	-	-	-	-
Net income	-3.68919M	-4.41978M	-2.60724M	-2.45858M	-2.40841M
Selling general administrative	2.60M	2.58M	2.34M	2.44M	2.13M
Selling and marketing expenses	0.23M	0.13M	-	-	0.13M
Gross profit	0.07M	-	0.13M	0.24M	0.03M
Reconciled depreciation	0.63M	0.55M	0.30M	0.08M	0.05M
Ebit	-3.59735M	-3.33076M	-2.61571M	-2.50177M	-2.42342M
Ebitda	-2.96263M	-2.78442M	-2.32009M	-2.42116M	-2.37194M
Depreciation and amortization	0.63M	0.55M	0.30M	0.08M	0.05M
Non operating income net other	-	-	-	-	-
Operating income	-4.16402M	-3.78279M	-2.61571M	-2.50177M	-2.42342M
Other operating expenses	3.89M	3.33M	2.75M	2.74M	2.45M
Interest expense	0.57M	0.19M	0.00000M	0.00000M	0.00000M
Tax provision	-	-	-	-	-
Interest income	-	-	0.00846M	0.04M	0.02M
Net interest income	-0.56667M	-0.18872M	0.00846M	0.04M	0.02M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	0.57M	0.19M	-	-	-
Total revenue	0.29M	0.00000M	0.13M	0.24M	0.03M
Total operating expenses	3.67M	3.33M	2.75M	2.74M	2.45M
Cost of revenue	0.22M	-	-	0.10M	-
Total other income expense net	0.47M	-0.90030M	0.00846M	0.04M	0.02M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-3.68919M	-4.41978M	-2.60724M	-2.45858M	-2.40841M
Net income applicable to common shares	-3.68919M	-4.41978M	-2.60724M	-2.45858M	-2.40841M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31
Total assets	2.85M	6.36M	5.51M	2.59M	4.75M
Intangible assets	0.30M	0.29M	0.25M	0.18M	0.13M
Earning assets	-	-	-	-	-
Other current assets	0.07M	0.10M	0.33M	-	-
Total liab	3.16M	4.09M	1.98M	0.33M	0.45M
Total stockholder equity	-0.31122M	2.27M	3.53M	2.27M	4.30M
Deferred long term liab	-	-	-	-	-
Other current liab	0.88M	0.73M	0.29M	0.14M	0.06M
Common stock	13.44M	11.61M	9.84M	6.55M	6.52M
Capital stock	13.44M	11.61M	9.84M	6.55M	-
Retained earnings	-16.69946M	-13.01027M	-8.59049M	-5.98324M	-3.52467M
Other liab	0.28M	1.11M	-	0.09M	0.13M
Good will	-	-	-	-	-
Other assets	-	-	-	0.17M	-
Cash	0.69M	1.49M	2.09M	0.41M	4.22M
Cash and equivalents	-	-	-	-	-
Total current liabilities	2.56M	1.66M	1.42M	0.23M	0.31M
Current deferred revenue	0.81M	0.04M	-	0.04M	0.04M
Net debt	1.15M	0.08M	-1.36402M	-0.41398M	-4.21785M
Short term debt	1.51M	0.24M	0.16M	-	-
Short long term debt	1.36M	0.06M	-	-	-
Short long term debt total	1.84M	1.57M	0.73M	-	-
Other stockholder equity	2.94M	3.67M	2.28M	1.70M	1.31M
Property plant equipment	1.08M	2.56M	1.77M	0.34M	0.16M
Total current assets	1.46M	3.51M	3.48M	1.90M	4.46M
Long term investments	-	-	-	-	-
Net tangible assets	-0.61504M	1.98M	3.28M	2.09M	4.18M
Short term investments	-	-	0.00000M	1.18M	3.50M
Net receivables	0.21M	0.21M	0.16M	0.24M	0.17M
Long term debt	0.13M	0.97M	0.04M	-	-
Inventory	0.49M	1.72M	0.91M	-	-
Accounts payable	0.16M	1.02M	0.96M	0.05M	0.22M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-	-	0.17M	0.29M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	1.39M	2.85M	2.02M	0.69M	0.29M
Capital lease obligations	0.35M	0.54M	0.69M	-	-
Long term debt total	-	-	-	-	-

Breakdown	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31
Investments	0.15M	-0.34509M	1.18M	2.33M	-2.70000M
Change to liabilities	-0.20201M	0.21M	0.92M	0.12M	0.34M
Total cashflows from investing activities	0.15M	-0.34509M	0.28M	2.01M	-2.89906M
Net borrowings	1.24M	1.41M	-0.06516M	-0.06516M	-0.06516M
Total cash from financing activities	1.89M	2.59M	3.31M	0.02M	4.73M
Change to operating activities	0.02M	0.08M	0.01M	0.00021M	-0.07565M
Net income	-3.68919M	-4.41978M	-2.60724M	-2.45858M	-2.40841M
Change in cash	-0.79975M	-0.59957M	1.68M	-0.30387M	3.26M
Begin period cash flow	1.49M	2.09M	0.41M	0.72M	0.96M
End period cash flow	0.69M	1.49M	2.09M	0.41M	4.22M
Total cash from operating activities	-2.84590M	-2.84948M	-1.89943M	-2.33306M	-1.26875M
Issuance of capital stock	0.00000M	0.81M	3.64M	0.00000M	-
Depreciation	0.63M	0.55M	0.30M	0.08M	0.05M
Other cashflows from investing activities	-	-	-0.01344M	-0.01344M	-0.01344M
Dividends paid	-	-	-	-	-
Change to inventory	0.00050M	-0.87890M	-0.90577M	-0.16667M	-0.16667M
Change to account receivables	-0.00236M	-0.05986M	0.09M	-0.06974M	-0.12932M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	1.96M	1.86M	-0.27212M	2.01M	-0.28062M
Change to netincome	0.39M	1.67M	0.28M	0.16M	0.95M
Capital expenditures	0.09M	0.35M	0.91M	0.32M	0.20M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-0.18245M	-0.64738M	0.13M	-0.31746M	0.11M
Stock based compensation	0.45M	0.63M	0.41M	0.40M	0.32M
Other non cash items	-0.05933M	1.04M	-0.13333M	-0.04000M	0.66M
Free cash flow	-2.93403M	-3.19457M	-2.80476M	-2.65077M	-1.46781M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
CTABF Canntab Therapeutics Limited	- -%	-	-	-	4.77	4.74	21.16	-0.8022
ZTS Zoetis Inc	0.95 1.25%	76.84	40.18	30.96	10.67	17.60	11.27	26.18
MKKGY Merck KGaA ADR	0.42 1.37%	30.98	21.25	14.93	3.10	2.14	3.60	12.98
MKGAF MERCK Kommanditgesellschaft auf Aktien	- -%	149.28	21.73	14.95	3.16	2.15	3.56	12.82
GALDY GALDERMA GROUP AG	0.48 1.12%	43.42	74.21	41.67	8.64	5.55	9.15	42.22

Reports Covered

View All

Profile

Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.

Canntab Therapeutics Limited

223 Riviera Drive, Markham, ON, Canada, L3R 5J6

289 301 3812
https://canntab.ca

Key Executives

Name	Title	Year Born
Mr. Richard C. Goldstein	Interim CEO, Co-Founder, CFO & Director	1961
Mr. Barry M. Polisuk B.A., LL.B	Sec. & Independent Director	1960
Mr. Joshi Laxminarayan	Chief Scientific Officer	NA
Mr. Eric Malinski	Director of Marketing	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.